- $11.27bn
- $12.04bn
- $4.37bn
- 81
- 34
- 17
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.36 | ||
| PEG Ratio (f) | 0.16 | ||
| EPS Growth (f) | 1,714.09% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.75 | ||
| Price to Tang. Book | 11.68 | ||
| Price to Free Cashflow | 15.89 | ||
| Price to Sales | 2.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.51% | ||
| Return on Equity | -29.57% | ||
| Operating Margin | -19.05% | ||
Financial Summary
| Year End 29th Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3,239 | 4,526 | 4,584 | 4,504 | 4,372 | 4,284.55 | 4,477.66 | 4.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -30.79 | +13.85 | n/a | n/a | n/a | n/a | +13.17 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Directors
- John Thompson NEC (72)
- Francis deSouza PRE (50)
- Sam Samad CFO (52)
- Robert Ragusa COO (61)
- Aimee Hoyt CHO (50)
- Joydeep Goswami SVP (49)
- Alex Aravanis CTO (45)
- Jose Torres CAO (46)
- Kathryne Reeves CMO (52)
- Charles Dadswell GCN (62)
- Phillip Febbo OTH (54)
- Susan Tousi OTH (51)
- Frances Arnold IND (64)
- Caroline Dorsa IND (62)
- Robert Epstein IND (66)
- Scott Gottlieb IND (48)
- Gary Guthart IND (55)
- Philip Schiller IND (60)
- Susan Siegel IND (60)
- Last Annual
- December 29th, 2024
- Last Interim
- December 29th, 2024
- Incorporated
- May 16th, 2000
- Public Since
- June 28th, 2000
- No. of Shareholders
- 497
- No. of Employees
- 8,970
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 158,263,015
- Address
- 5200 Illumina Way, SAN DIEGO, 92122-4616
- Web
- https://www.illumina.com
- Phone
- +1 8582024500
- Auditors
- Ernst & Young LLP
Latest News for ILMN
Upcoming Events for ILMN
Q1 2025 Illumina Inc Earnings Release
Q1 2025 Illumina Inc Earnings Call
Illumina Inc Annual Shareholders Meeting
Q2 2025 Illumina Inc Earnings Release
Similar to ILMN
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 21:14 UTC, shares in Illumina are trading at $71.20. This share price information is delayed by 15 minutes.
Shares in Illumina last closed at $71.20 and the price had moved by -38.06% over the past 365 days. In terms of relative price strength the Illumina share price has underperformed the S&P500 Index by -41.76% over the past year.
The overall consensus recommendation for Illumina is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIllumina does not currently pay a dividend.
Illumina does not currently pay a dividend.
Illumina does not currently pay a dividend.
To buy shares in Illumina you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $71.20, shares in Illumina had a market capitalisation of $11.27bn.
Here are the trading details for Illumina:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ILMN
Based on an overall assessment of its quality, value and momentum Illumina is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Illumina is $117.01. That is 64.34% above the last closing price of $71.20.
Analysts covering Illumina currently have a consensus Earnings Per Share (EPS) forecast of $4.46 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Illumina. Over the past six months, its share price has underperformed the S&P500 Index by -45.99%.
As of the last closing price of $71.20, shares in Illumina were trading -41.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Illumina PE ratio based on its reported earnings over the past 12 months is 15.36. The shares last closed at $71.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Illumina's management team is headed by:
- John Thompson - NEC
- Francis deSouza - PRE
- Sam Samad - CFO
- Robert Ragusa - COO
- Aimee Hoyt - CHO
- Joydeep Goswami - SVP
- Alex Aravanis - CTO
- Jose Torres - CAO
- Kathryne Reeves - CMO
- Charles Dadswell - GCN
- Phillip Febbo - OTH
- Susan Tousi - OTH
- Frances Arnold - IND
- Caroline Dorsa - IND
- Robert Epstein - IND
- Scott Gottlieb - IND
- Gary Guthart - IND
- Philip Schiller - IND
- Susan Siegel - IND